Fast track designation to leronlimab for breast cancer

The FDA granted fast track designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer.

Leronlimab (PRO 140, CytoDyn Inc.) is an investigational humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor believed to play key roles in tumor invasion and metastasis.

Agents that block CCR5 have been shown to block tumor metastases in laboratory and animal models of aggressive breast cancer and prostate cancer.

“This [fast track designation] is an important acknowledgement of the potentially paradigm-shifting therapy option in metastatic triple-negative breast cancer,” Richard Pestell, MD, PhD, vice chairman and chief medical officer of CytoDyn, said in a company-issued press release. “Currently, there are no enduring treatment options for [patients with metastatic triple-negative breast cancer] and we thank the FDA for recognizing the potential of leronlimab [in this setting].”

Enrollment is underway for a study designed to evaluate the agent for patients with metastatic triple-negative breast cancer.

CytoDyn expects to submit a biologics license application to the FDA this year for leronlimab as part of combination therapy for patients with HIV.

The CCR5 receptor also may play a key role in modulating immune cell trafficking to sites of inflammation.

CytoDyn is conducting a phase 2 study of leronlimab to support the concept that the CCR5 receptor on engrafted cells is key for the development of acute graft-versus-host disease. The FDA previously granted orphan drug designation to leronlimab for the prevention of GVHD.

Explore more about oncology and research in the field at: http://bit.ly/2xaW3zT

Source: https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B1bd93db0-7445-455b-bbd1-d2700e3e8cf1%7D/fda-grants-fast-track-designation-to-leronlimab-for-metastatic-triple-negative-breast-cancer

Biological age and breast cancer risk

Biological age, estimated by measuring DNA methylation, appeared to be a predictor for breast cancer risk, according to study results.

“[When looking] at a group of people who are all the same age, some may be perfectly healthy while others are not,” Jacob K. Kresovich, PhD, MPH, a postdoctoral fellow in the molecular and genetic epidemiology group of the National Institute of Environmental Health Sciences, said in a press release. “That variability in health may be better captured by biologic age than chronologic age.”

Because chronological age is a leading risk factor for breast cancer, Kresovich and colleagues hypothesized that biological age acceleration may be associated with increased breast cancer risk.

They measured baseline blood DNA methylation in 2,764 women enrolled in the Sister Study, including 1,566 women who developed breast cancer within years after baseline blood draw.

Researchers used three established methylation-based biological “clocks” and defined biological age acceleration for each woman by comparing estimated biological age with chronological age.

Results showed a significant association between biological age acceleration and increased risk for breast cancer (HR = 1.15; 95% CI, 1.07-1.23).

Explore more about hematology oncology at World Hematology 2019, this July at Rome, Italy. For more info, PS: https://hematology.cmesociety.com/

Source: https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B2d7e000a-e544-4b24-b435-f054012c680e%7D/older-biological-age-may-increase-breast-cancer-risk

Track 19 : Hematology & Oncology: Case Reports

Case reports are detailed reports that has all the signs, symptoms, diagnosis, treatment and follow up of the patients. These case reports serve as an evidence for medicine, scientific and educational purposes. Case reports of hemotology or oncology gives the information of preventive or therapeutic interventions as these generally require stronger evidence. Thus, a case report has all the details of a disease or a disorder of an individual in medical field. Case reports give the demographic profile of the patient suffering from disease, references of any unusual or unique incidences, etc.

Do submit your abstracts in the following link: Abstract-Submission

Alcohol consumption and Multiple Myeloma

Research has shown that high alcohol consumption impairs the immune system and, in turn, increases cancer risk.  However, low alcohol consumption improves insulin sensitivity, which, in turn, decreases risk of diabetes and other obesity-related disorders and thus, indirectly, may decrease risk of multiple myeloma.

Source: https://www.mdedge.com/hematology-oncology/quiz/7735/multiple-myeloma/alcohol-consumption-and-multiple-myeloma?channel=250

Track 18 : Diagnostic and Equipment Market

The major driving factors for hematology and oncology diagnostics market include increasing incidences of blood related disorders and cancers.

The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research.

The global hematology diagnostics market size was estimated at USD 5.96 billion in 2017. It is anticipated to expand at a CAGR of 5.85% over the forecast period. Nearly 1 million new cases of blood cancer are expected to be diagnosed by 2020, which is anticipated to account for nearly 6.0% of all new cancer. Furthermore, a significant number of the world population have different hemoglobinopathies. High prevalence of blood disorders, such as thalassemia is anticipated to boost the demand for hematology testing.

To explore more about hematology/ oncology, PS: http://bit.ly/2xaW3zT

Source of info: https://www.grandviewresearch.com/industry-analysis/hematology-diagnostics-market | https://www.marketresearch.com/MarketsandMarkets-v3719/Interventional-Oncology-Product-Radiofrequency-microwave-12290878/